Jillian R. Haney

Jillian R. Haney

Auto-generated profile, based on publicly available information

Jillian R. Haney

Department of Psychiatry, Semel Institute, David Geffen School of Medicine, University of California, Los Angeles, 695 Charles E. Young Drive South, Los Angeles, CA 90095, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2020 in Biological Psychiatry
Verified
Journal Article
Open access
LHLeanna M. Hernandez
Leanna M. Hernandez
MKMinsoo Kim
Minsoo Kim
GHGil D. Hoftman
Gil D. Hoftman
JHJillian R. Haney
Jillian R. Haney
LTLuis de la Torre-Ubieta
Luis de la Torre-Ubieta
MGMichael J. Gandal
Michael J. Gandal
Over the past decade, large-scale genetic studies have successfully identified hundreds of genetic variants robustly associated with risk for psychiatric disorders. However, mechanistic insight -- and clinical translation -- continues to lag the pace of risk variant identification, hindered by the sheer number of targets, their predominant non-coding localization, as well as pervasive pleiotropy and incomplete penetrance. Successful next steps require identification of ‘causal’ genetic variants and their proximal biological consequences; placing variants within biologically-defined functional contexts, reflecting specific molecular pathways, cell-types, circuits, and developmental windows; and characterizing the downstream, convergent neurobiological impact of polygenicity within an individual. Here, we discuss opportunities and challenges of high-throughput transcriptomic profiling in human brain, and how transcriptomics can help pinpoint mechanisms underlying genetic risk for psychiatric disorders at a scale necessary to tackle daunting levels of polygenicity. These include transcriptome-wide association studies (TWAS) and related approaches for candidate risk gene prioritization through integration of GWAS with expression quantitative trait loci (eQTL). We outline transcriptomic results informing our understanding of the brain-level molecular pathology of psychiatric disorders, including autism (ASD), bipolar disorder (BD), major depression (MDD), and schizophrenia (SCZ). Finally, we discuss systems-level approaches for integration of distinct genetic, genomic and phenotypic levels, including combining spatially-resolved gene expression and human neuroimaging maps. Results highlight the importance of understanding gene expression (dys)regulation across human brain development as a major contributor to psychiatric disease pathogenesis, from common variants acting as expression quantitative trait loci (eQTL) to rare variants enriched for gene expression regulatory pathways.